Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer

Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer , delayed the progression of kidney cancer when used in combination with Pfizer's Inlyta drug in a late-stage study.